Comparison between cryotherapy and topical zinc sulfate with cryotherapy and placebo in common wart treatment

Comparing the efficacy of topical Niosomal Zinc Sulfate plus cryotherapy and placebo plus cryotherapy in the treatment of Verruca Vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017100936660N1

Enrollment

Registered

2017-10-27

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

verruca vulgaris. viral warts

Interventions

Intervention 1: intervention: cryotherapy of lesions every other week plus application of topical niosomal zinc sulfate two times a day until complete remission or for maximum duration of 3 month. Int

Treatment - Drugs

Placebo

intervention: cryotherapy of lesions every other week plus application of topical niosomal zinc sulfate two times a day until complete remission or for maximum duration of 3 month

control: cryotherapy of lesions every other week plus application of placebo two times a day until complete remission or for maximum duration of 3 months

Eligibility

Sex/Gender

All

Age

12 Years to 50 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: consent to participate; verruca vulgaris patients with minimum of one lesion that has minimum diameter of 6 millimeter exclusion criteria: lesions on face, genitalia and periungual; patients under 12 and above 50 years; immune suppression; pregnancy and lactating; patients who has received any treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Size of lesion. Timepoint: before intervention, 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: scaling with ruler( in millimeter).;Treatment sessions number. Timepoint: every other week until complete resolusion or up to 3 months. Method of measurement: counting.	—

Secondary

Measure	Time frame
Hyperpigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Hypopigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Blister. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Pain. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.;Pruritus. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.	—

Measure

Time frame

Hyperpigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Hypopigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Blister. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Pain. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.;Pruritus. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFahameh Fadaeiresketi

Kerman University of Medical Sciences

f.fadaei@kmu.ac.ir+98 34 3132 8328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026